PPCB (Propanc Biopharma) Total Assets: $14.33 Mil (As of Mar. 2026)


PPCB Propanc Biopharma Inc PPCB
29 GF Score
Price $1.48
! 2 Warning Signs
View Full Analysis

What is Propanc Biopharma Total Assets?

Propanc Biopharma PPCB 29 Total Assets is $14.33 Mil as of Mar. 2026. GuruFocus rates PPCB with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Propanc Biopharma's Total Assets for the quarter that ended in Mar. 2026 was $14.33 Mil.

During the past 12 months, Propanc Biopharma's average Total Assets Growth Rate was 38370.60% per year. During the past 3 years, the average Total Assets Growth Rate was 531.30% per year. During the past 5 years, the average Total Assets Growth Rate was 181.70% per year. During the past 10 years, the average Total Assets Growth Rate was 11.80% per year.

During the past 13 years, Propanc Biopharma's highest 3-Year average Total Assets Growth Rate was 531.30%. The lowest was -86.60%. And the median was 3.60%.

Total Assets is connected with ROA %. Propanc Biopharma's annualized ROA % for the quarter that ended in Mar. 2026 was -172.79%. Total Assets is also linked to Revenue through Asset Turnover. Propanc Biopharma's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

Propanc Biopharma  (NAS:PPCB) Total Assets Explanation

Total Assets is connected with ROA %.

Propanc Biopharma's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-25.44/( (15.112+14.334)/ 2 )
=-25.44/14.723
=-172.79 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Propanc Biopharma's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (15.112+14.334)/ 2 )
=0/14.723
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Propanc Biopharma Total Assets Related Terms

Propanc Biopharma Total Assets Historical Data

* Premium members only.

The historical data trend for Propanc Biopharma's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Propanc Biopharma Total Assets Chart

Propanc Biopharma Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.08 0.06 0.07 19.63

Propanc Biopharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.53 19.63 17.98 15.11 14.33
PPCB
29GF Score
Propanc Biopharma Inc PPCB
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Propanc Biopharma Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Propanc Biopharma's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (A: Jun. 2025 )+Total Liabilities (A: Jun. 2025 )
=13.906+5.726
=19.63

Propanc Biopharma's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=10.828+3.506
=14.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $14.33 Mil mean?
Propanc Biopharma (PPCB) has a Total Assets of $14.33 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Propanc Biopharma and its competitors.
Is Propanc Biopharma's Total Assets too high?
Propanc Biopharma's current Total Assets is $14.33 Mil. Overall, Propanc Biopharma has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Propanc Biopharma's Total Assets compare to ENSC and ACUT?
Propanc Biopharma's Total Assets of $14.33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Propanc Biopharma and its competitors. Propanc Biopharma's current Total Assets is $14.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Propanc Biopharma stock overvalued right now?
Propanc Biopharma (PPCB) has a current Total Assets of $14.33 Mil. The current Total Assets is $14.33 Mil. Propanc Biopharma's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Propanc Biopharma (PPCB), the current Total Assets is $14.33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Propanc Biopharma Business Description

Address 302, 6 Butler Street, Cambwerwell, VIC, AUS, 3124
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
29GF Score

Get the complete analysis for PPCB

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.48
Price